Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fosamprenavir: drug development for adherence.

E Kelly Hester1, Haley V Chandler, Kelli M Sims

  • 1Department of Pharmacy Practice, Harrison School of Pharmacy, Auburn University, AL 36849, USA. hesteek@auburn.edu

The Annals of Pharmacotherapy
|June 8, 2006
PubMed
Summary

Fosamprenavir, an HIV-1 protease inhibitor prodrug, offers comparable efficacy and safety to amprenavir with a reduced pill burden. This antiretroviral agent is useful for both treatment-naïve and experienced HIV patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhancing learner abilities to address health disparities during ambulatory care Introductory Pharmacy Practice Experiences (IPPE).

Currents in pharmacy teaching & learning·2024
Same author

Consensus recommendations for the use of novel antiretrovirals in persons with HIV who are heavily treatment-experienced and/or have multidrug-resistant HIV-1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy.

Pharmacotherapy·2024
Same author

Consensus recommendations for the use of novel antiretrovirals in persons with HIV who are heavily treatment-experienced and/or have multidrug-resistant HIV-1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy: An executive summary.

Pharmacotherapy·2024
Same author

Weight Changes With Integrase Strand Transfer Inhibitor Therapy in the Management of HIV Infection: A Systematic Review.

The Annals of pharmacotherapy·2022
Same author

Assessing student confidence in interprofessional communication during primary care advanced pharmacy practice experiences (APPEs).

Currents in pharmacy teaching & learning·2020
Same author

Doravirine: A Return of the NNRTI Class?

The Annals of pharmacotherapy·2019

Area of Science:

  • Antiviral drug research
  • HIV/AIDS therapeutics
  • Pharmacology and pharmacokinetics

Background:

  • Fosamprenavir is a prodrug of amprenavir, designed to simplify HIV-1 treatment regimens.
  • Amprenavir, the active moiety, is metabolized by CYP3A4, influencing drug interactions.
  • The development aimed to reduce the pill burden associated with amprenavir therapy.

Purpose of the Study:

  • To comprehensively review the pharmacology, pharmacokinetics, virology, safety, efficacy, and clinical applications of fosamprenavir.
  • To assess the role of fosamprenavir in the management of HIV-1 infection.

Main Methods:

  • Conducted a MEDLINE search (1966-July 2005) using keywords: fosamprenavir, Lexiva, amprenavir, and GW433908.
  • Reviewed abstracts from infectious diseases and HIV scientific meetings.

Related Experiment Videos

  • Included data from in vitro, preclinical, and Phase II/III clinical trials, along with published and unpublished information.

    • Main Results:

    • Fosamprenavir demonstrated efficacy comparable to amprenavir, with the significant advantage of a reduced pill burden.
    • The drug exhibited a safety profile consistent with other protease inhibitors (PIs).
    • Limited cross-resistance was observed with other PIs, suggesting utility in various treatment scenarios.

    Conclusions:

    • Fosamprenavir is a valuable antiretroviral agent for HIV-1 treatment, offering favorable efficacy and tolerability.
    • Current data support the use of fosamprenavir in both treatment-naïve and protease inhibitor-experienced HIV-infected individuals.